- Home
- SQFT vs IMRN Comparison
SQFT vs IMRN Comparison
Compare SQFT & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SQFT
- IMRN
- Stock Information
- Founded
- SQFT 1999
- IMRN 1994
- Country
- SQFT United States
- IMRN Australia
- Employees
- SQFT N/A
- IMRN N/A
- Industry
- SQFT Real Estate Investment Trusts
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- SQFT Real Estate
- IMRN Health Care
- Exchange
- SQFT Nasdaq
- IMRN Nasdaq
- Market Cap
- SQFT 7.7M
- IMRN 9.2M
- IPO Year
- SQFT 2020
- IMRN N/A
- Fundamental
- Price
- SQFT $5.59
- IMRN $2.14
- Analyst Decision
- SQFT
- IMRN
- Analyst Count
- SQFT 0
- IMRN 0
- Target Price
- SQFT N/A
- IMRN N/A
- AVG Volume (30 Days)
- SQFT 988.5K
- IMRN 74.3K
- Earning Date
- SQFT 11-11-2025
- IMRN 08-29-2025
- Dividend Yield
- SQFT N/A
- IMRN N/A
- EPS Growth
- SQFT N/A
- IMRN N/A
- EPS
- SQFT N/A
- IMRN N/A
- Revenue
- SQFT $18,052,597.00
- IMRN $4,777,422.00
- Revenue This Year
- SQFT $23.63
- IMRN N/A
- Revenue Next Year
- SQFT N/A
- IMRN N/A
- P/E Ratio
- SQFT N/A
- IMRN N/A
- Revenue Growth
- SQFT N/A
- IMRN 48.63
- 52 Week Low
- SQFT $4.19
- IMRN $1.50
- 52 Week High
- SQFT $23.00
- IMRN $2.73
- Technical
- Relative Strength Index (RSI)
- SQFT 47.62
- IMRN 66.27
- Support Level
- SQFT $5.20
- IMRN $1.87
- Resistance Level
- SQFT $6.22
- IMRN $2.30
- Average True Range (ATR)
- SQFT 0.52
- IMRN 0.09
- MACD
- SQFT -0.07
- IMRN 0.02
- Stochastic Oscillator
- SQFT 25.47
- IMRN 65.96
About SQFT Presidio Property Trust Inc.
Presidio Property Trust Inc is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties. Presidio's model homes are leased to homebuilders located in Arizona, Illinois, Texas, Wisconsin, and Florida. The office, industrial and retail properties are located in Colorado, with properties also located in Maryland, North Dakota, Texas, and Southern California.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.